ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Geron Corporation (GERN) Report Updated: Jun 21, 2016 | Print This Page

Get more stock ratings by Louis Navellier

Geron Corporation (GERN)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Biotechnology
Competitors: ATHX,LXRX,FPRX,AVXL

Stock Analysis

Rating: Monthly View

A
B
C
D
F
June July August September October November December January February March April May

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

Geron Corporation© quotemedia

Company Profile

Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.